On 18 September 2012, members of the Policy Affairs Working Group attended an event hosted by the European Alliance for Personalised Medicines (EAPM).
Commissioner for Health and Consumers John Dalli, told participants of the importance of imaging technologies and in-vitro diagnostic medical devices (IVDs) to the development of personalized medicines.
Commissioner Dalli stressed that we can no longer be satisfied with finding out what kind of disease a patient has, we must find out what kind of patient is being affected by the disease. He also stressed that such imaging technologies are of key importance in the prevention of adverse reactions to medicines.
